B. P. Valderrama

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.

J. Witjes, M. Galsky, M. Milowsky, 2021, The New England journal of medicine.

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.

N. Matsubara, S. Banek, Spyros Triantos, 2023, The New England journal of medicine.

Progress in systemic therapy for advanced-stage urothelial carcinoma

J. Bellmunt, B. P. Valderrama, Rosa Nadal, 2023, Nature reviews. Clinical oncology.

Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study.

M. A. Climent, R. Morales-Barrera, E. González-Billalabeitia, 2024, ESMO open.

Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.

M. S. van der Heijden, M. D. Galsky, M. Claps, 2024, Journal of Clinical Oncology.

Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.

M. Burotto, G. Sonpavde, M. Galsky, 2023, The New England journal of medicine.